Journal of Allergy and Clnical Immunology

Feed Category: 

Reply

We appreciate Li and Liu1 for their interests in and comments on our article.2 Although most patients with severe coronavirus disease 2019 (COVID-19) have a self-limited disease course, about 10% to 15% subsequently developed critical illness and experienced a high mortality.3,4 In our randomized controlled trial, we evaluated whether the use of ruxolitinib was safe and superior in shortening the time to recovery and in preventing severe COVID-19 from progression. Given below are our point-to-point responses to each of the comments.

Feed Item Url: 
https://www.jacionline.org/article/S0091-6749(20)31233-1/abstract?rss=yes

Regarding “Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial”

We read with great interest the article titled ‘‘Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial’’ by Cao et al.1 The study, which finally included 41 patients, evaluated the efficacy and safety of ruxolitinib for severe COVID-19 cases. They finally found that ruxolitinib recipients had a significant chest computed tomography (CT) improvement, a faster recovery from lymphopenia, and favorable side-effect profile. However, we think it is appropriate to comment on the methods used in this study.

Feed Item Url: 
https://www.jacionline.org/article/S0091-6749(20)31232-X/abstract?rss=yes

A substantial neutrophilic inflammation as regular part of severe type 2 chronic rhinosinusitis with nasal polyps

Capsule Summary: We show that severe type 2 CRSwNP patients display a profound neutrophilic inflammation, with increased activation status and proteolytic activity, co-existing with severe eosinophilia (EETosis and CLC-deposition), and independent of IL-17.

Feed Item Url: 
https://www.jacionline.org/article/S0091-6749(20)31275-6/abstract?rss=yes